

# Antimicrobial Resistance (AMR) Surveillance Report

**Hospital name:** Angkor Hospital for Children  
**Country name:** Cambodia

**Data from:**  
**01 Jan 2016 to 31 Dec 2016**

**Contact person:** Paul Turner  
**Contact address:** Tep Vong (Achamean) Road & Oum Chhay Street, Siem Reap  
**Contact email:** pault@tropmedres.ac  
**Generated on:** 24 Mar 2020

**Generated by**

AutoMated tool for Antimicrobial resistance Surveillance System (AMASS)

Version 1.0 (released on February 1, 2019)

The AMASS application is available under the Creative Commons Attribution 4.0 International Public License (CC BY 4.0). The application can be downloaded at: <http://www.amass.website>

The AMASS application used microbiology\_data and hospital\_admission\_data files that are stored in the same folder as the application (AMASS.bat) to generate this report.

The goal of the AMASS application is to enable hospitals with microbiology data available in electronic formats to analyze their own data and generate AMR surveillance reports promptly. If hospital admission date data are available, the reports will additionally be stratified by infection origin (community–origin or hospital–origin). If mortality data (such as patient discharge outcome data) are available, a report on mortality involving AMR infection will be added.

This automatically generated report has limitations, and requires users to understand those limitations and use the summary data in the report with careful interpretation.

A valid report could have local implications and much wider benefits if shared with national and international organizations.

This automatically generated report is under the jurisdiction of the hospital to copy, redistribute, and share with any individual or organization.

This automatically generated report contains no patient identifier, similar to standard reports on cumulative antimicrobial susceptibility.

For any query on AMASS, please contact:  
Cherry Lim (cherry@tropmedres.ac) and  
Direk Limmathurotsakul (direk@tropmedres.ac)

**Suggested title for citation:**

Antimicrobial resistance surveillance report, Angkor Hospital for Children, Cambodia, 01 Jan 2016 to 31 Dec 2016.

# Content

Introduction .....01

Section [1]: Data overview .....03

Section [2]: Isolate–based surveillance report .....05

Section [3]: Isolate–based surveillance report with stratification by infection origin .....12

Section [4]: Sample–based surveillance report .....24

Section [5]: Sample–based surveillance report with stratification by infection origin .....27

Section [6]: Mortality involving AMR and antimicrobial–susuceptible infections .....32

Methods .....38

Acknowledgements ..... 43

# Introduction

Antimicrobial resistance (AMR) is a global health crisis [1]. The report by Lord Jim O'Neill estimated that 700,000 global deaths could be attributable to AMR in 2015, and projected that the annual death toll could reach 10 million by 2050 [1]. However, data of AMR surveillance from low and middle-income countries (LMICs) are scarce [1,2], and data of mortality associated with AMR infections are rarely available. A recent study estimated that 19,000 deaths are attributable to AMR infections in Thailand annually, using routinely available microbiological and hospital databases [3]. The study also proposed that hospitals in LMICs should utilize routinely available microbiological and hospital admission databases to generate reports on AMR surveillance systematically [3].

Reports on AMR surveillance can have a wide range of benefits [2]; including

- characterization of the frequency of resistance and organisms in different facilities and regions;
- prospective and retrospective information on emerging public health threats;
- evaluation and optimization of local and national standard treatment guidelines;
- evaluation of the impact of interventions beyond antimicrobial guidelines that aim to reduce AMR; and
- data sharing with national and international organizations to support decisions on resource allocation for interventions against AMR and to inform the implementation of action plans at national and global levels.

When reporting AMR surveillance results, it is generally recommended that (a) duplicate results of bacterial isolates are removed, and (b) reports are stratified by infection origin (community-origin or hospital-origin), if possible [2]. Many hospitals in LMICs lack time and resources needed to analyze the data (particularly to deduplicate data and to generate tables and figures), write the reports, and to release the data or reports [4].

AutoMated tool for Antimicrobial resistance Surveillance System (AMASS) was developed as an offline, open-access and easy-to-use application that allows a hospital to perform data analysis independently and generate isolate-based and sample-based surveillance reports stratified by infection origin from routinely collected electronic databases. The application was built in R, which is a free software environment. The application has been placed within a user-friendly interface that only requires the user to double-click on the application icon. The AMASS application can be downloaded at:

<http://www.amass.website>

Please note that the AMASS application and the automatically-generated report have limitations, and require readers to understand those limitations and review the reports and summary data carefully. We encourage the user of the AMASS application to perform manual validation (such as printing and listing isolates of the species to cross check with the reports), as recommended by Clinical and Laboratory Standards Institute (CLSI) [5] and European Antimicrobial Resistance Surveillance Network (EUCAST) [6,7]. Moreover, it is important to note that the AMASS is an add-on automatized report generating tool and does not replace WHONET, Laboratory Information System (LIS), quality assurance programme, or antimicrobial surveillance systems (including the WHO GLASS).

---

**References:**

- [1] O'Neill J. (2014) Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Review on antimicrobial resistance. <http://amr-review.org>. (accessed on 3 Dec 2018).
- [2] World Health Organization (2018) Global Antimicrobial Resistance Surveillance System (GLASS) Report. Early implantation 2016–2017. <http://apps.who.int/iris/bitstream/handle/10665/259744/9789241513449-eng.pdf>. (accessed on 3 Dec 2018)
- [3] Lim C., et al. (2016) Epidemiology and burden of multidrug-resistant bacterial infection in a developing country. *Elife* 5: e18082.
- [4] Ashley EA, Shetty N, Patel J, et al. Harnessing alternative sources of antimicrobial resistance data to support surveillance in low-resource settings. *J Antimicrob Chemother*. 2019; 74(3):541–546.
- [5] Clinical and Laboratory Standards Institute (CLSI). Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data, 4th Edition. 2014. (accessed on 21 Jan 2020)
- [6] European Antimicrobial Resistance Surveillance Network (EARS-Net). Antimicrobial resistance (AMR) reporting protocol 2018. (accessed on 21 Jan 2020)
- [7] European Committee on Antimicrobial Susceptibility Testing (EUCAST). [www.eucast.org](http://www.eucast.org) (accessed on 21 Jan 2020)

# Section [1]: Data overview

## Introduction

An overview of the data detected by the AMASS application is generated by default. The summary is based on the raw data files saved within the same folder as the application file (AMASS.bat).

Please review and validate this section carefully before proceeds to the next section.

## Results

The microbiology\_data file (stored in the same folder as the application file) had:

**3325** specimen data records with collection dates ranging from  
**01 Jan 2016** to **31 Dec 2016**

The hospital\_admission\_data file (stored in the same folder as the application file) had:

**19394** admission data records with hospital admission dates ranging from  
**01 Oct 2015** to **31 Dec 2016**

## Notes:

[1] If the periods of the data in microbiology\_data and hospital\_admission\_data files are not similar, the automatically-generated report should be interpreted with caution. The AMASS generates the reports based on the available data.

**Reporting period by months:**

Data was stratified by month to assist detection of missing data, and verification of whether the month distribution of data records in microbiology\_data file and hospital\_admission\_data file reflected the microbiology culture frequency and admission rate of the hospital, respectively. For example if the number of specimens in the microbiology\_data file reported below is lower than what is expected, please check the raw data file and data dictionary files.

Month	Number of specimen data records in microbiology_data file	Number of admission data records in hospital_admission_data file
January	257	350
February	253	360
March	278	349
April	234	354
May	276	360
June	286	356
July	293	394
August	294	386
September	278	349
October	318	752
November	289	725
December	269	748
Total:	3325	19394

**Note:**

[1] Additional general demographic data will be made available in the next version of the AMASS application.

## Section [2]: Isolate–based surveillance report

### Introduction

An isolate–based surveillance report is generated by default, even if the hospital\_admission\_data file is unavailable. This is to enable hospitals with only microbiology data available to utilize the de–duplication and report generation functions of AMASS. This report is without stratification by origin of infection.

The report generated by the AMASS application version 1.0 includes only blood samples. The next version of AMASS will include other specimen types, including cerebrospinal fluid (CSF), urine, stool, and other specimens.

### Organisms under this survey:

- *Staphylococcus aureus*
- *Enterococcus* spp.
- *Streptococcus pneumoniae*
- *Salmonella* spp.
- *Escherichia coli*
- *Klebsiella pneumoniae*
- *Pseudomonas aeruginosa*
- *Acinetobacter* spp.

### Results

The microbiology\_data file had:

*Sample collection dates ranged from*     **01 Jan 2016** to **31 Dec 2016**

*Number of records of blood specimens collected within the above date range:*

**3173 blood specimens records**

*Number of records of blood specimens with \*negative culture (no growth):*

**2949 blood specimens records**

*Number of records of blood specimens with culture positive for a microorganism:*

**224 blood specimens records**

*Number of records of blood specimens with culture positive for organism under this survey:*

**56 blood specimens records**



The AMASS application de-duplicated the data by including only the first isolate per patient per specimen type per evaluation period as described in the method. The number of patients with positive samples is as follows:

Organism	Number of records of blood specimens culture positive for the organism	**Number of patients with blood culture positive for the organism (de-duplicated)
<i>Staphylococcus aureus</i>	10	10
<i>Enterococcus</i> spp.	1	1
<i>Streptococcus pneumoniae</i>	7	7
<i>Salmonella</i> spp.	6	6
<i>Escherichia coli</i>	12	9
<i>Klebsiella pneumoniae</i>	9	8
<i>Pseudomonas aeruginosa</i>	5	5
<i>Acinetobacter</i> spp.	6	6
Total:	56	52

\*The negative culture included data values specified as 'no growth' in the dictionary\_for\_microbiology\_data file (details on data dictionary files are in the method section) to represent specimens with negative culture for any microorganism.


\*\*Only the first isolate for each patient per specimen type, per pathogen, and per evaluation period was included in the analysis.

The following figures and tables show the proportion of patients with blood culture positive for antimicrobial non-susceptible isolates.

Section [2]: Isolate-based surveillance report

Blood: *Staphylococcus aureus*


( No. of patients = 10 )



Antibiotic agent	% NS (n)	95% CI
Methicillin	10% (1/10)	2%–40%
Vancomycin	NA	–
Clindamycin	100% (1/1)	21%–100%

Blood: *Enterococcus* spp.

( No. of patients = 1 )




Antibiotic agent	% NS (n)	95% CI
Ampicillin	100% (1/1)	21%–100%
Vancomycin	0% (0/1)	0%–79%
Teicoplanin	NA	–
Linezolid	NA	–
Daptomycin	NA	–

\*Proportion of non-susceptible isolates (% NS) represents the number of patients with blood culture positive for non-susceptible isolates (numerator) over the total number of patients with blood culture positive for the organism and the organism was tested for susceptibility against the antibiotic (denominator). The AMASS application de-duplicated the data by including only the first isolate per patient per specimen type per evaluation period. Grey bars indicate that testing with the antibiotic occurred for less than 70% of the total number of patients with blood culture positive for the organism. CI = confidence interval; NA = Not available/reported/tested; Methicillin: methicillin, oxacillin, or cefoxitin

Section [2]: Isolate-based surveillance report

Blood: *Streptococcus pneumoniae*


( No. of patients = 7 )



Antibiotic agent	% NS (n)	95% CI
Penicillin G	NA	–
Oxacillin	100% (7/7)	65%–100%
Co-trimoxazole	100% (7/7)	65%–100%
3GC	NA	–
Ceftriaxone	NA	–
Cefotaxime	NA	–
Erythromycin	57% (4/7)	25%–84%
Clindamycin	43% (3/7)	16%–75%
Levofloxacin	NA	–

Blood: *Salmonella* spp.

( No. of patients = 6 )




Antibiotic agent	% NS (n)	95% CI
FLUOROQUINOLONES	83% (5/6)	44%–97%
Ciprofloxacin	83% (5/6)	44%–97%
Levofloxacin	NA	–
3GC	17% (1/6)	3%–56%
Ceftriaxone	17% (1/6)	3%–56%
Cefotaxime	NA	–
Ceftazidime	NA	–
CARBAPENEMS	NA	–
Imipenem	NA	–
Meropenem	NA	–
Ertapenem	NA	–
Doripenem	NA	–

\*Proportion of non-susceptible isolates (% NS) represents the number of patients with blood culture positive for non-susceptible isolates (numerator) over the total number of patients with blood culture positive for the organism and the organism was tested for susceptibility against the antibiotic (denominator). The AMASS application de-duplicated the data by including only the first isolate per patient per specimen type per evaluation period. Grey bars indicate that testing with the antibiotic occurred for less than 70% of the total number of blood culture positive for the organism.  
CI = confidence interval; NA = Not available/reported/tested; 3GC = 3rd-generation cephalosporin;  
FLUOROQUINOLONES: ciprofloxacin or levofloxacin; CARBAPENEMS: imipenem, meropenem, ertapenem or doripenem

Section [2]: Isolate-based surveillance report

Blood: *Escherichia coli* ( No. of patients = 9 )




Antibiotic agent	% NS (n)	95% CI
Gentamicin	44% (4/9)	19%–73%
Amikacin	NA	–
Co-trimoxazole	89% (8/9)	57%–98%
Ampicillin	56% (5/9)	27%–81%
FLUOROQUINOLONES	56% (5/9)	27%–81%
Ciprofloxacin	56% (5/9)	27%–81%
Levofloxacin	NA	–
3GC	78% (7/9)	45%–94%
Cefpodoxime	78% (7/9)	45%–94%
Ceftriaxone	78% (7/9)	45%–94%
Cefotaxime	NA	–
Ceftazidime	78% (7/9)	45%–94%
Cefepime	NA	–
CARBAPENEMS	0% (0/9)	0%–30%
Imipenem	0% (0/5)	0%–43%
Meropenem	0% (0/4)	0%–49%
Ertapenem	NA	–
Doripenem	NA	–
Colistin	NA	–

\*Proportion of non-susceptible isolates (% NS) represents the number of patients with blood culture positive for non-susceptible isolates (numerator) over the total number of patients with blood culture positive for the organism and the organism was tested for susceptibility against the antibiotic (denominator). The AMASS application de-duplicated the data by including only the first isolate per patient per specimen type per evaluation period. Grey bars indicate that testing with the antibiotic occurred for less than 70% of the total number of blood culture positive for the organism.  
CI = confidence interval; NA = Not available/reported/tested; 3GC = 3rd-generation cephalosporin;  
FLUOROQUINOLONES: ciprofloxacin or levofloxacin; CARBAPENEMS: imipenem, meropenem, ertapenem or doripenem

Section [2]: Isolate-based surveillance report

Blood: *Klebsiella pneumoniae* ( No. of patients = 8 )




\*Proportion of non-susceptible isolates (% NS) represents the number of patients with blood culture positive for non-susceptible isolates (numerator) over the total number of patients with blood culture positive for the organism and the organism was tested for susceptibility against the antibiotic (denominator). The AMASS application de-duplicated the data by including only the first isolate per patient per specimen type per evaluation period. Grey bars indicate that testing with the antibiotic occurred for less than 70% of the total number of blood culture positive for the organism.  
CI = confidence interval; NA = Not available/reported/tested; 3GC = 3rd-generation cephalosporin;  
FLUOROQUINOLONES: ciprofloxacin or levofloxacin; CARBAPENEMS: imipenem, meropenem, ertapenem or doripenem

Section [2]: Isolate-based surveillance report

Blood: *Pseudomonas aeruginosa*


( No. of patients = 5 )



Antibiotic agent	% NS (n)	95% CI
Ceftazidime	0% (0/5)	0%–43%
Ciprofloxacin	0% (0/5)	0%–43%
Piperacillin/tazobactam	NA	–
AMINOGLYCOSIDES	0% (0/5)	0%–43%
Gentamicin	0% (0/5)	0%–43%
Amikacin	NA	–
CARBAPENEMS	20% (1/5)	4%–62%
Imipenem	50% (1/2)	9%–91%
Meropenem	0% (0/3)	0%–56%
Doripenem	NA	–
Colistin	NA	–

Blood: *Acinetobacter* spp.

( No. of patients = 6 )



Antibiotic agent	% NS (n)	95% CI
Tigecycline	NA	–
Minocycline	NA	–
AMINOGLYCOSIDES	17% (1/6)	3%–56%
Gentamicin	17% (1/6)	3%–56%
Amikacin	NA	–
CARBAPENEMS	0% (0/6)	0%–39%
Imipenem	0% (0/2)	0%–66%
Meropenem	0% (0/4)	0%–49%
Doripenem	NA	–
Colistin	NA	–

\*Proportion of non-susceptible isolates (% NS) represents the number of patients with blood culture positive for non-susceptible isolates (numerator) over the total number of patients with blood culture positive for the organism and the organism was tested for susceptibility against the antibiotic (denominator). The AMASS application de-duplicated the data by including only the first isolate per patient per specimen type per evaluation period. Grey bars indicate that testing with the antibiotic occurred for less than 70% of the total number of blood culture positive for the organism.  
CI = confidence interval; NA = Not available/reported/tested; AMINOGLYCOSIDES: either gentamicin or amikacin;  
CARBAPENEMS: imipenem, meropenem, ertapenem or doripenem

## Section [3]: Isolate–based surveillance report with stratification by infection origin

### Introduction

An isolate–based surveillance report with stratification by origin of infection is generated only if admission date data are available in the raw data file(s) with the appropriate specification in the data dictionaries.

Stratification by origin of infection is used as a proxy to define where the bloodstream infection (BSI) was contracted (hospital versus community).

The definitions of infection origin proposed by the WHO GLASS are used. In brief, community–origin BSI is defined as patients in the hospital for less than or equal to two calendar days when the first specimen culture positive for the pathogen was taken. Hospital–origin BSI is defined as patients admitted for more than two calendar days when the first specimen culture positive for the pathogen was taken.

### Results:

The data included in the analysis to generate the report had:

*Sample collection dates ranged from*     **01 Jan 2016** to **31 Dec 2016**

*\*Number of patients with blood culture positive for pathogen under the survey:*

**52 patients**

*\*\*Number of patients with community–origin BSI:*

**31 patients**

*\*\*Number of patients with hospital–origin BSI:*

**21 patients**

*\*\*\*Number of patients with unknown infection of origin status:*

**0 patients**



Organism	Number of patients with blood culture positive for the organism	Community –origin**	Hospital –origin**	Unknown origin***
<i>Staphylococcus aureus</i>	10	8	2	0
<i>Enterococcus</i> spp.	1	0	1	0
<i>Streptococcus pneumoniae</i>	7	7	0	0
<i>Salmonella</i> spp.	6	4	2	0
<i>Escherichia coli</i>	9	5	4	0
<i>Klebsiella pneumoniae</i>	8	2	6	0
<i>Pseudomonas aeruginosa</i>	5	2	3	0
<i>Acinetobacter</i> spp.	6	3	3	0
<b>Total:</b>	<b>52</b>	<b>31</b>	<b>21</b>	<b>0</b>

**Note:**

NA= Not applicable (hospital admission date or infection origin data are not available)

\*Only the first isolate for each patient per specimen type per pathogen under the reporting period is included in the analysis. Please refer to Section [2] for details on how this number was calculated from the raw microbiology\_data file.

\*\*The definitions of infection origin proposed by the WHO GLASS is used. In brief, community–origin BSI was defined as patients in the hospital for less than or equal to two calendar days when the first blood culture positive for the pathogen was taken. Hospital–origin BSI was defined as patients admitted for more than two calendar days when the first specimen culture positive for the pathogen was taken.

Please refer to the 'Methods' section for more details on the definitions used.


\*\*\*Unknown origin could be because admission date data are not available or the patient was not hospitalised.

The following figures and tables below show the proportion of patients with blood culture positive for antimicrobial non–susceptible isolates stratified by infection of origin.




Section [3]: Isolate-based surveillance report  
with stratification by infection origin

Blood: *Staphylococcus aureus*      Community-origin ( *No. of patients = 8* )



Antibiotic agent	% NS (n)	95% CI
Methicillin	0% (0/8)	0%–32%
Vancomycin	NA	–
Clindamycin	NA	–

Blood: *Staphylococcus aureus*      Hospital-origin ( *No. of patients = 2* )




Antibiotic agent	% NS (n)	95% CI
Methicillin	50% (1/2)	9%–91%
Vancomycin	NA	–
Clindamycin	100% (1/1)	21%–100%

\*Proportion of non-susceptible isolates (% NS) represents the number of patients with blood culture positive for non-susceptible isolates (numerator) over the total number of patients with blood culture positive for the organism and the organism was tested for susceptibility against the antibiotic (denominator). The AMASS application de-duplicated the data by including only the first isolate per patient per specimen type per evaluation period. Grey bars indicate that testing with the antibiotic occurred for less than 70% of the total number of patients with blood culture positive for the organism. CI = confidence interval; NA = Not available/reported/tested; Methicillin: methicillin, oxacillin, or cefoxitin

Section [3]: Isolate–based surveillance report  
with stratification by infection origin

Blood: *Enterococcus* spp.


Community–origin ( *No. of patients = 0* )



Antibiotic agent	% NS (n)	95% CI
Ampicillin	NA	–
Vancomycin	NA	–
Teicoplanin	NA	–
Linezolid	NA	–
Daptomycin	NA	–

Blood: *Enterococcus* spp.

Hospital–origin ( *No. of patients = 1* )




Antibiotic agent	% NS (n)	95% CI
Ampicillin	100% (1/1)	21%–100%
Vancomycin	0% (0/1)	0%–79%
Teicoplanin	NA	–
Linezolid	NA	–
Daptomycin	NA	–

\*Proportion of non–susceptible isolates (% NS) represents the number of patients with blood culture positive for non–susceptible isolates (numerator) over the total number of patients with blood culture positive for the organism and the organism was tested for susceptibility against the antibiotic (denominator). The AMASS application de–duplicated the data by including only the first isolate per patient per specimen type per evaluation period. Grey bars indicate that testing with the antibiotic occurred for less than 70% of the total number of patients with blood culture positive for the organism. CI = confidence interval; NA = Not available/reported/tested; Methicillin: methicillin, oxacillin, or cefoxitin


Section [3]: Isolate-based surveillance report with stratification by infection origin

Blood: Streptococcus pneumoniae Community-origin ( No. of patients = 7 )



Antibiotic agent	% NS (n)	95% CI
Penicillin G	NA	–
Oxacillin	100% (7/7)	65%–100%
Co-trimoxazole	100% (7/7)	65%–100%
3GC	NA	–
Ceftriaxone	NA	–
Cefotaxime	NA	–
Erythromycin	57% (4/7)	25%–84%
Clindamycin	43% (3/7)	16%–75%
Levofloxacin	NA	–

Blood: Streptococcus pneumoniae Hospital-origin ( No. of patients = 0 )




Antibiotic agent	% NS (n)	95% CI
Penicillin G	NA	–
Oxacillin	NA	–
Co-trimoxazole	NA	–
3GC	NA	–
Ceftriaxone	NA	–
Cefotaxime	NA	–
Erythromycin	NA	–
Clindamycin	NA	–
Levofloxacin	NA	–

\*Proportion of non-susceptible isolates (% NS) represents the number of patients with blood culture positive for non-susceptible isolates (numerator) over the total number of patients with blood culture positive for the organism and the organism was tested for susceptibility against the antibiotic (denominator). The AMASS application de-duplicated the data by including only the first isolate per patient per specimen type per evaluation period. Grey bars indicate that testing with the antibiotic occurred for less than 70% of the total number of blood culture positive for the organism. CI = confidence interval; NA = Not available/reported/tested; 3GC = 3rd-generation cephalosporin; FLUOROQUINOLONES: ciprofloxacin or levofloxacin; CARBAPENEMS: imipenem, meropenem, ertapenem or doripenem

Section [3]: Isolate-based surveillance report  
with stratification by infection origin


Blood: *Salmonella* spp.



Community-origin ( *No. of patients = 4* )

Antibiotic agent	% NS (n)	95% CI
FLUOROQUINOLONES	75% (3/4)	30%–95%
Ciprofloxacin	75% (3/4)	30%–95%
Levofloxacin	NA	–
3GC	25% (1/4)	5%–70%
Ceftriaxone	25% (1/4)	5%–70%
Cefotaxime	NA	–
Ceftazidime	NA	–
CARBAPENEMS	NA	–
Imipenem	NA	–
Meropenem	NA	–
Ertapenem	NA	–
Doripenem	NA	–

Blood: *Salmonella* spp.



Hospital-origin ( *No. of patients = 2* )


Antibiotic agent	% NS (n)	95% CI
FLUOROQUINOLONES	100% (2/2)	34%–100%
Ciprofloxacin	100% (2/2)	34%–100%
Levofloxacin	NA	–
3GC	0% (0/2)	0%–66%
Ceftriaxone	0% (0/2)	0%–66%
Cefotaxime	NA	–
Ceftazidime	NA	–
CARBAPENEMS	NA	–
Imipenem	NA	–
Meropenem	NA	–
Ertapenem	NA	–
Doripenem	NA	–

\*Proportion of non-susceptible isolates (% NS) represents the number of patients with blood culture positive for non-susceptible isolates (numerator) over the total number of patients with blood culture positive for the organism and the organism was tested for susceptibility against the antibiotic (denominator). The AMASS application de-duplicated the data by including only the first isolate per patient per specimen type per evaluation period. Grey bars indicate that testing with the antibiotic occurred for less than 70% of the total number of blood culture positive for the organism.  
CI = confidence interval; NA = Not available/reported/tested; 3GC = 3rd-generation cephalosporin;  
FLUOROQUINOLONES: ciprofloxacin or levofloxacin; CARBAPENEMS: imipenem, meropenem, ertapenem or doripenem

Section [3]: Isolate-based surveillance report  
with stratification by infection origin

Blood: *Escherichia coli*

Community-origin ( *No. of patients = 5* )




Antibiotic agent	% NS (n)	95% CI
Gentamicin	40% (2/5)	12%–77%
Amikacin	NA	–
Co-trimoxazole	80% (4/5)	38%–96%
Ampicillin	60% (3/5)	23%–88%
FLUOROQUINOLONES	60% (3/5)	23%–88%
Ciprofloxacin	60% (3/5)	23%–88%
Levofloxacin	NA	–
3GC	60% (3/5)	23%–88%
Cefpodoxime	60% (3/5)	23%–88%
Ceftriaxone	60% (3/5)	23%–88%
Cefotaxime	NA	–
Ceftazidime	60% (3/5)	23%–88%
Cefepime	NA	–
CARBAPENEMS	0% (0/5)	0%–43%
Imipenem	0% (0/2)	0%–66%
Meropenem	0% (0/3)	0%–56%
Ertapenem	NA	–
Doripenem	NA	–
Colistin	NA	–

\*Proportion of non-susceptible isolates (% NS) represents the number of patients with blood culture positive for non-susceptible isolates (numerator) over the total number of patients with blood culture positive for the organism and the organism was tested for susceptibility against the antibiotic (denominator). The AMASS application de-duplicated the data by including only the first isolate per patient per specimen type per evaluation period. Grey bars indicate that testing with the antibiotic occurred for less than 70% of the total number of blood culture positive for the organism.  
CI = confidence interval; NA = Not available/reported/tested; 3GC = 3rd-generation cephalosporin;  
FLUOROQUINOLONES: ciprofloxacin or levofloxacin; CARBAPENEMS: imipenem, meropenem, ertapenem or doripenem

Section [3]: Isolate-based surveillance report  
with stratification by infection origin

Blood: *Escherichia coli* Hospital-origin ( No. of patients = 4 )




Antibiotic agent	% NS (n)	95% CI
Gentamicin	50% (2/4)	15%–85%
Amikacin	NA	–
Co-trimoxazole	100% (4/4)	51%–100%
Ampicillin	50% (2/4)	15%–85%
FLUOROQUINOLONES	50% (2/4)	15%–85%
Ciprofloxacin	50% (2/4)	15%–85%
Levofloxacin	NA	–
3GC	100% (4/4)	51%–100%
Cefpodoxime	100% (4/4)	51%–100%
Ceftriaxone	100% (4/4)	51%–100%
Cefotaxime	NA	–
Ceftazidime	100% (4/4)	51%–100%
Cefepime	NA	–
CARBAPENEMS	0% (0/4)	0%–49%
Imipenem	0% (0/3)	0%–56%
Meropenem	0% (0/1)	0%–79%
Ertapenem	NA	–
Doripenem	NA	–
Colistin	NA	–

\*Proportion of non-susceptible isolates (% NS) represents the number of patients with blood culture positive for non-susceptible isolates (numerator) over the total number of patients with blood culture positive for the organism and the organism was tested for susceptibility against the antibiotic (denominator). The AMASS application de-duplicated the data by including only the first isolate per patient per specimen type per evaluation period. Grey bars indicate that testing with the antibiotic occurred for less than 70% of the total number of blood culture positive for the organism.  
CI = confidence interval; NA = Not available/reported/tested; 3GC = 3rd-generation cephalosporin;  
FLUOROQUINOLONES: ciprofloxacin or levofloxacin; CARBAPENEMS: imipenem, meropenem, ertapenem or doripenem

Section [3]: Isolate-based surveillance report  
with stratification by infection origin

Blood: *Klebsiella pneumoniae*

Community-origin ( *No. of patients = 2* )




Antibiotic agent	% NS (n)	95% CI
Gentamicin	0% (0/2)	0%–66%
Amikacin	NA	–
Co-trimoxazole	0% (0/2)	0%–66%
FLUOROQUINOLONES	0% (0/2)	0%–66%
Ciprofloxacin	0% (0/2)	0%–66%
Levofloxacin	NA	–
3GC	0% (0/2)	0%–66%
Cefpodoxime	0% (0/2)	0%–66%
Ceftriaxone	0% (0/2)	0%–66%
Cefotaxime	NA	–
Ceftazidime	0% (0/2)	0%–66%
Cefepime	NA	–
CARBAPENEMS	0% (0/2)	0%–66%
Imipenem	0% (0/2)	0%–66%
Meropenem	NA	–
Ertapenem	NA	–
Doripenem	NA	–
Colistin	NA	–

\*Proportion of non-susceptible isolates (% NS) represents the number of patients with blood culture positive for non-susceptible isolates (numerator) over the total number of patients with blood culture positive for the organism and the organism was tested for susceptibility against the antibiotic (denominator). The AMASS application de-duplicated the data by including only the first isolate per patient per specimen type per evaluation period. Grey bars indicate that testing with the antibiotic occurred for less than 70% of the total number of blood culture positive for the organism.  
CI = confidence interval; NA = Not available/reported/tested; 3GC = 3rd-generation cephalosporin;  
FLUOROQUINOLONES: ciprofloxacin or levofloxacin; CARBAPENEMS: imipenem, meropenem, ertapenem or doripenem



Section [3]: Isolate-based surveillance report  
with stratification by infection origin

Blood: *Klebsiella pneumoniae*      Hospital-origin      ( No. of patients = 6 )




Antibiotic agent	% NS (n)	95% CI
Gentamicin	17% (1/6)	3%–56%
Amikacin	NA	–
Co-trimoxazole	67% (4/6)	30%–90%
FLUOROQUINOLONES	33% (2/6)	10%–70%
Ciprofloxacin	33% (2/6)	10%–70%
Levofloxacin	NA	–
3GC	50% (3/6)	19%–81%
Cefpodoxime	50% (3/6)	19%–81%
Ceftriaxone	50% (3/6)	19%–81%
Cefotaxime	NA	–
Ceftazidime	50% (3/6)	19%–81%
Cefepime	NA	–
CARBAPENEMS	0% (0/6)	0%–39%
Imipenem	0% (0/2)	0%–66%
Meropenem	0% (0/4)	0%–49%
Ertapenem	NA	–
Doripenem	NA	–
Colistin	NA	–

\*Proportion of non-susceptible isolates (% NS) represents the number of patients with blood culture positive for non-susceptible isolates (numerator) over the total number of patients with blood culture positive for the organism and the organism was tested for susceptibility against the antibiotic (denominator). The AMASS application de-duplicated the data by including only the first isolate per patient per specimen type per evaluation period. Grey bars indicate that testing with the antibiotic occurred for less than 70% of the total number of blood culture positive for the organism.  
CI = confidence interval; NA = Not available/reported/tested; 3GC = 3rd-generation cephalosporin;  
FLUOROQUINOLONES: ciprofloxacin or levofloxacin; CARBAPENEMS: imipenem, meropenem, ertapenem or doripenem




Section [3]: Isolate-based surveillance report with stratification by infection origin

Blood: *Pseudomonas aeruginosa*      Community-origin ( No. of patients = 2 )



Antibiotic agent	% NS (n)	95% CI
Ceftazidime	0% (0/2)	0%–66%
Ciprofloxacin	0% (0/2)	0%–66%
Piperacillin/tazobactam	NA	–
AMINOGLYCOSIDES	0% (0/2)	0%–66%
Gentamicin	0% (0/2)	0%–66%
Amikacin	NA	–
CARBAPENEMS	0% (0/2)	0%–66%
Imipenem	0% (0/1)	0%–79%
Meropenem	0% (0/1)	0%–79%
Doripenem	NA	–
Colistin	NA	–

Blood: *Pseudomonas aeruginosa*      Hospital-origin ( No. of patients = 3 )




Antibiotic agent	% NS (n)	95% CI
Ceftazidime	0% (0/3)	0%–56%
Ciprofloxacin	0% (0/3)	0%–56%
Piperacillin/tazobactam	NA	–
AMINOGLYCOSIDES	0% (0/3)	0%–56%
Gentamicin	0% (0/3)	0%–56%
Amikacin	NA	–
CARBAPENEMS	33% (1/3)	6%–79%
Imipenem	100% (1/1)	21%–100%
Meropenem	0% (0/2)	0%–66%
Doripenem	NA	–
Colistin	NA	–

\*Proportion of non-susceptible isolates (% NS) represents the number of patients with blood culture positive for non-susceptible isolates (numerator) over the total number of patients with blood culture positive for the organism and the organism was tested for susceptibility against the antibiotic (denominator). The AMASS application de-duplicated the data by including only the first isolate per patient per specimen type per evaluation period. Grey bars indicate that testing with the antibiotic occurred for less than 70% of the total number of blood culture positive for the organism.  
CI = confidence interval; NA = Not available/reported/tested; AMINOGLYCOSIDES: either gentamicin or amikacin; CARBAPENEMS: imipenem, meropenem, ertapenem or doripenem

Section [3]: Isolate-based surveillance report with stratification by infection origin

Blood: *Acinetobacter* spp.


Community-origin ( *No. of patients = 3* )



Antibiotic agent	% NS (n)	95% CI
Tigecycline	NA	–
Minocycline	NA	–
AMINOGLYCOSIDES	0% (0/3)	0%–56%
Gentamicin	0% (0/3)	0%–56%
Amikacin	NA	–
CARBAPENEMS	0% (0/3)	0%–56%
Imipenem	0% (0/1)	0%–79%
Meropenem	0% (0/2)	0%–66%
Doripenem	NA	–
Colistin	NA	–

Blood: *Acinetobacter* spp.

Hospital-origin ( *No. of patients = 3* )



Antibiotic agent	% NS (n)	95% CI
Tigecycline	NA	–
Minocycline	NA	–
AMINOGLYCOSIDES	33% (1/3)	6%–79%
Gentamicin	33% (1/3)	6%–79%
Amikacin	NA	–
CARBAPENEMS	0% (0/3)	0%–56%
Imipenem	0% (0/1)	0%–79%
Meropenem	0% (0/2)	0%–66%
Doripenem	NA	–
Colistin	NA	–

\*Proportion of non-susceptible isolates (% NS) represents the number of patients with blood culture positive for non-susceptible isolates (numerator) over the total number of patients with blood culture positive for the organism and the organism was tested for susceptibility against the antibiotic (denominator). The AMASS application de-duplicated the data by including only the first isolate per patient per specimen type per evaluation period. Grey bars indicate that testing with the antibiotic occurred for less than 70% of the total number of blood culture positive for the organism.  
CI = confidence interval; NA = Not available/reported/tested; AMINOGLYCOSIDES: either gentamicin or amikacin; CARBAPENEMS: imipenem, meropenem, ertapenem or doripenem

## Section [4]: Sample-based surveillance report

### Introduction

A sample-based surveillance report is generated if data of culture negative is available.

The sample-based approach involves the collection of data on all blood samples taken for microbiological testing and includes information on the number of positive blood samples for a specific specimen type (both pathogens under the survey and other bacteria) as well as number of negative (no microbial growth) samples. After removal of duplicate results and assuming that routine blood culture testing is applied systematically, we can use the number of tested patients as a proxy for a number of patients with new cases of bloodstream infection (BSI).

### Results:

The microbiology\_data file had:

*Specimen collection dates ranged from* **01 Jan 2016 to 31 Dec 2016**

*Number of records on blood specimen collected within the above date range:*

**3173 blood specimen records**

*\*Number of patients sampled for blood culture within the above date range:*


**2360 patients sampled for blood culture**

### Note:

\*Number of patients sampled for blood culture is used as denominator to estimate the frequency of infections per 100,000 tested patients

The following figures show the frequency of infections for patients with blood culture tested.

Section [4]: Sample-based surveillance report



\*We apologise that the bacteria name in the table and in the figure are not written in italic. This is because of the R command we used. We will improve this in the next version.


\*\*Frequency of infection per 100,000 tested patients represents the number of patients with blood culture positive for a pathogen (numerator) over the total number of tested patients (denominator). The AMASS application de-duplicates the data by included only the first isolate of each patient per specimen type per reporting period.

CI = confidence interval; NS = non-susceptible; NA = Not available/reported/tested; 3GC = 3rd-generation cephalosporin

## Section [4]: Sample-based surveillance report

**Blood: \*AMR pathogens under this surveillance**

( No. of patients = 2360 )



Organism	**Frequency (95% CI)
MRSA	43 (8–240)
Vancomycin–NS Enterococcus spp.	0 (0–163)
Penicillin–NS S. pneumoniae	0 (0–163)
Fluoroquinolone–NS Salmonella spp.	212 (91–496)
3GC–NS E. coli	297 (144–612)
Carbapenem–NS E. coli	0 (0–163)
3GC–NS K. pneumoniae	128 (44–374)
Carbapenem–NS K. pneumoniae	0 (0–163)
Carbapenem–NS P. aeruginosa	43 (8–240)
Carbapenem–NS Acinetobacter spp.	0 (0–163)

\*We apologise that the bacteria name in the table and in the figure are not written in italic. This is because of the R command we used. We will improve this in the next version.

\*\*Frequency of infection per 100,000 tested patients represents the number of patients with blood culture positive for a pathogen (numerator) over the total number of tested patients (denominator). The AMASS application de-duplicates the data by included only the first isolate of each patient per specimen type per reporting period.

CI = confidence interval; NS = non-susceptible; NA = Not available/reported/tested; 3GC = 3rd-generation cephalosporin

## Section [5]: Sample-based surveillance report with stratification by infection origin

### Introduction

A sample-based surveillance report with stratification by origin of infection is generated only if data of culture negative is available and admission date or a variable containing the classification is available in the raw data file with the appropriate specification in the data dictionaries.

### Results:

The data included in the analysis had:

*Specimen collection dates ranged from* **01 Jan 2016 to 31 Dec 2016**

*Number of records on blood specimen collected within the above date range:*

**3173 blood specimen records**

*Number of patients sampled for blood culture within the above date range:*

**2360 patients sampled for blood culture**

**2010** *patients had at least one admission having the first blood culture drawn within first 2 calendar days of hospital admission.*

*This parameter is used as a denominators for frequency of community-origin bacteraemia (per 100,000 patients tested for blood culture on admission).*

**179** *patients had at least one admission having the first blood culture drawn after 2 calendar days of hospital admission.*

*This parameter is used as a denominators for frequency of hospital-origin bacteraemia (per 100,000 patients tested for blood culture for HAI).*

**200** *patients had a blood drawn for culture and with unknown origin of infection. Validation of this statistics is highly recommended.*

### Note:

**29** *patients had more than one admissions, of which at least one admission had the first blood culture drawn within the first 2 calendar days of hospital admission AND at least one admission had the first blood culture drawn after 2 calendar days of hospital admission.*


The following figures show the frequency of infections for patients with blood culture tested and stratified by infection origin, under this surveillance.





Section [5]: Sample-based surveillance report with stratification by infection origin

Blood:      \*Pathogens      Hospital-origin      ( No. of patients = 179 )



Organism	**Frequency (95% CI)
S. aureus	1118 (307–3982)
Enterococcus spp.	559 (99–3097)
S. pneumoniae	0 (0–2101)
Salmonella spp.	1118 (307–3982)
E. coli	2235 (873–5604)
K. pneumoniae	3352 (1546–7119)
P. aeruginosa	1676 (572–4811)
Acinetobacter spp.	1676 (572–4811)

\*We apologise that the bacteria name in the table and in the figure are not written in italic. This is because of the R command we used. We will improve this in the next version.

\*\*Frequency of infection per 100,000 tested population at risk of HAI represents the number of patients with blood culture positive for a pathogen (numerator) over the total number of tested population at risk of HAI (denominator). The AMASS application de-duplicates the data by included only the first isolate of each patient per specimen type per reporting period.


CI = confidence interval; NS = non-susceptible; NA = Not available/reported/tested; 3GC = 3rd-generation cephalosporin



Section [5]: Sample-based surveillance report with stratification by infection origin

Blood: \*AMR pathogens

Community-origin ( No. of patients = 2010 )



Organism	**Frequency (95% CI)
MRSA	0 (0–191)
Vancomycin–NS Enterococcus spp.	0 (0–191)
Penicillin–NS S. pneumoniae	0 (0–191)
Fluoroquinolone–NS Salmonella spp.	150 (51–438)
3GC–NS E. coli	150 (51–438)
Carbapenem–NS E. coli	0 (0–191)
3GC–NS K. pneumoniae	0 (0–191)
Carbapenem–NS K. pneumoniae	0 (0–191)
Carbapenem–NS P. aeruginosa	0 (0–191)
Carbapenem–NS Acinetobacter spp.	0 (0–191)


\*We apologise that the bacteria name in the table and in the figure are not written in italic. This is because of the R command we used. We will improve this in the next version.

\*\*Frequency of infection per 100,000 tested patients represents the number of patients with blood culture positive for a pathogen (numerator) over the total number of tested patients (denominator). The AMASS application de-duplicates the data by included only the first isolate of each patient per specimen type per reporting period.

CI = confidence interval; NS = non-susceptible; NA = Not available/reported/tested; 3GC = 3rd-generation cephalosporin

Section [5]: Sample-based surveillance report with stratification by infection origin

Blood: \*AMR pathogens Hospital-origin ( No. of patients = 179 )



Organism	**Frequency (95% CI)
MRSA	559 (99–3097)
Vancomycin–NS Enterococcus spp.	0 (0–2101)
Penicillin–NS S. pneumoniae	0 (0–2101)
Fluoroquinolone–NS Salmonella spp.	1118 (307–3982)
3GC–NS E. coli	2235 (873–5604)
Carbapenem–NS E. coli	0 (0–2101)
3GC–NS K. pneumoniae	1676 (572–4811)
Carbapenem–NS K. pneumoniae	0 (0–2101)
Carbapenem–NS P. aeruginosa	559 (99–3097)
Carbapenem–NS Acinetobacter spp.	0 (0–2101)

\*We apologise that the bacteria name in the table and in the figure are not written in italic. This is because of the R command we used. We will improve this in the next version.

\*\*Frequency of infection per 100,000 tested patients represents the number of patients with blood culture positive for a pathogen (numerator) over the total number of tested patients (denominator). The AMASS application de-duplicates the data by included only the first isolate of each patient per specimen type per reporting period.

CI = confidence interval; NS = non-susceptible; NA = Not available/reported/tested; 3GC = 3rd-generation cephalosporin

## Section [6] Mortality involving AMR and antimicrobial–susceptible infections

### Introduction

A surveillance report on mortality involving AMR infections and antimicrobial–susceptible infections with stratification by origin of infection is generated only if data on patient outcomes (i.e. discharge status) are available. Antimicrobial–resistant infection is a threat to modern health care, and the impact of the infection on patient outcomes is largely unknown. Performing analyses and generating reports on mortality often takes time and resources.

The term 'mortality involving AMR and antimicrobial–susceptible infections' was used because the mortality reported was all–cause mortality. This measure of mortality included deaths caused by or related to other underlying and intermediate causes.

Here, AMASS summarized the overall mortality of patients with antimicrobial–resistant and antimicrobial–susceptible bacteria bloodstream infections (BSI).

### Results:

The data included in the analysis had:

*Sample collection dates ranged from*     **01 Jan 2016** to **31 Dec 2016**

*Number of patients with blood culture positive for the organism under the survey:*

**52 patients**

*Number of patients with community–origin BSI:*

**31 patients**

*Number of patients with hospital–origin BSI:*

**21 patients**

The hospital admission data file had:

*Hospital admission dates ranging from*     **01 Oct 2015** to **31 Dec 2016**

*Number of records in the raw hospital admission data:*

**19394 records**

*Number of patients included in the analysis (de–duplicated):*

**4647 patients**

*Number of patients had death as outcome in any admission data records:*

**149 patients**

*Overall mortality:*

**3% (149/4647)**

The AMASS application merged the microbiology data file and hospital admission data file. The merged dataset was then de-duplicated so that only the first isolate per patient per specimen per reporting period was included in the analysis. The de-duplicated data was stratified by infection origin (community-origin infection or hospital-origin infection).


Organism	Mortality in patients with Community-origin BSI	Mortality in patients with Hospital-origin BSI
<i>Staphylococcus aureus</i>	0% (0/8)	0% (0/2)
<i>Enterococcus</i> spp.	NaN% (0/0)	100% (1/1)
<i>Streptococcus pneumoniae</i>	0% (0/7)	NaN% (0/0)
<i>Salmonella</i> spp.	25% (1/4)	0% (0/2)
<i>Escherichia coli</i>	40% (2/5)	75% (3/4)
<i>Klebsiella pneumoniae</i>	50% (1/2)	33% (2/6)
<i>Pseudomonas aeruginosa</i>	50% (1/2)	100% (3/3)
<i>Acinetobacter</i> spp.	0% (0/3)	33% (1/3)
Total:	16% (5/31)	48% (10/21)

The following figures and tables show the mortality of patients who were blood culture positive for antimicrobial non-susceptible and susceptible isolates.

Section [6] Mortality involving AMR and antimicrobial-susceptible infections

*Staphylococcus aureus*


Community-origin ( No. of patients = 8 )



Type of pathogen	Mortality (n)	95% CI
MRSA	NA	–
MSSA	0% (0/8)	0%–32%

*Staphylococcus aureus*


Hospital-origin ( No. of patients = 2 )



Type of pathogen	Mortality (n)	95% CI
MRSA	0% (0/1)	0%–79%
MSSA	0% (0/1)	0%–79%

*Enterococcus spp.*


Community-origin ( No. of patients = 0 )



Type of pathogen	Mortality (n)	95% CI
Vancomycin-NS	NA	–
Vancomycin-S	NA	–

*Enterococcus spp.*

Hospital-origin ( No. of patients = 1 )




Type of pathogen	Mortality (n)	95% CI
Vancomycin-NS	NA	–
Vancomycin-S	100% (1/1)	21%–100%

\*Mortality is the proportion (%) of in-hospital deaths (all-cause deaths). This represents the number of in-hospital deaths (numerator) over the total number of patients with blood culture positive for the organism and the type of pathogen (denominator). The AMASS application de-duplicates the data by included only the first isolate per patient per specimen type per evaluation period. NS = non-susceptible; S = susceptible; CI = confidence interval; Fluoroquinolone-NS = NS to any fluoroquinolone tested; 3GC-NS = NS to any 3rd-generation cephalosporin and susceptible to carbapenem

Section [6] Mortality involving AMR and antimicrobial-susceptible infections

*Streptococcus pneumoniae*


Community-origin ( No. of patients = 7 )



Mortality	Mortality (n)	95% CI
Penicillin-NS	NA	–
Penicillin-S	NA	–

*Streptococcus pneumoniae*


Hospital-origin ( No. of patients = 0 )



Type of pathogen	Mortality (n)	95% CI
Penicillin-NS	NA	–
Penicillin-S	NA	–

*Salmonella* spp.


Community-origin ( No. of patients = 4 )



Type of pathogen	Mortality (n)	95% CI
Fluoroquinolone-NS	33% (1/3)	6%–79%
Fluoroquinolone-S	0% (0/1)	0%–79%

*Salmonella* spp.

Hospital-origin ( No. of patients = 2 )




Type of pathogen	Mortality (n)	95% CI
Fluoroquinolone-NS	0% (0/2)	0%–66%
Fluoroquinolone-S	NA	–

\*Mortality is the proportion (%) of in-hospital deaths (all-cause deaths). This represents the number of in-hospital deaths (numerator) over the total number of patients with blood culture positive for the organism and the type of pathogen (denominator). The AMASS application de-duplicates the data by included only the first isolate per patient per specimen type per evaluation period. NS = non-susceptible; S = susceptible; CI = confidence interval; Fluoroquinolone-NS = NS to any fluoroquinolone tested; 3GC-NS = NS to any 3rd-generation cephalosporin and susceptible to carbapenem

Section [6] Mortality involving AMR and antimicrobial-susceptible infections

*Escherichia coli*


Community-origin ( No. of patients = 5 )



Type of pathogen	Mortality (n)	95% CI
Carbapenem-NS	NA	–
3GC-NS	33% (1/3)	6%–79%
Carbapenem-S and 3GC-S	50% (1/2)	9%–91%

*Escherichia coli*


Hospital-origin ( No. of patients = 4 )



Type of pathogen	Mortality (n)	95% CI
Carbapenem-NS	NA	–
3GC-NS	75% (3/4)	30%–95%
Carbapenem-S and 3GC-S	NA	–

*Klebsiella pneumoniae*


Community-origin ( No. of patients = 2 )



Type of pathogen	Mortality (n)	95% CI
Carbapenem-NS	NA	–
3GC-NS	NA	–
Carbapenem-S and 3GC-S	50% (1/2)	9%–91%

*Klebsiella pneumoniae*

Hospital-origin ( No. of patients = 6 )



Type of pathogen	Mortality (n)	95% CI
Carbapenem-NS	NA	–
3GC-NS	67% (2/3)	21%–94%
Carbapenem-S and 3GC-S	0% (0/3)	0%–56%


\*Mortality is the proportion (%) of in-hospital deaths (all-cause deaths). This represents the number of in-hospital deaths (numerator) over the total number of patients with blood culture positive for the organism and the type of pathogen (denominator). The AMASS application de-duplicates the data by including only the first isolate per patient per specimen type per evaluation period. NS = non-susceptible; S = susceptible; CI = confidence interval; Carbapenem-NS = NS to any carbapenems tested; 3GC-NS = NS to any 3rd-generation cephalosporin and susceptible to carbapenem



Section [6] Mortality involving AMR and antimicrobial-susceptible infections

*Pseudomonas aeruginosa*


Community-origin ( No. of patients = 2 )



Type of pathogen	Mortality (n)	95% CI
Carbapenem-NS	NA	–
Carbapenem-S	50% (1/2)	9%–91%

*Pseudomonas aeruginosa*


Hospital-origin ( No. of patients = 3 )



Type of pathogen	Mortality (n)	95% CI
Carbapenem-NS	100% (1/1)	21%–100%
Carbapenem-S	100% (2/2)	34%–100%

*Acinetobacter* spp.


Community-origin ( No. of patients = 3 )



Type of pathogen	Mortality (n)	95% CI
Carbapenem-NS	NA	–
Carbapenem-S	0% (0/3)	0%–56%

*Acinetobacter* spp.

Hospital-origin ( No. of patients = 3 )



Type of pathogen	Mortality (n)	95% CI
Carbapenem-NS	NA	–
Carbapenem-S	33% (1/3)	6%–79%

\*Mortality is the proportion (%) of in-hospital deaths (all-cause deaths). This represents the number of in-hospital deaths (numerator) over the total number of patients with blood culture positive for the organism and the type of pathogen (denominator). The AMASS application de-duplicates the data by including only the first isolate per patient per specimen type per evaluation period. NS = non-susceptible; S = susceptible; CI = confidence interval; Carbapenem-NS = NS to any carbapenems tested; 3GC-NS = NS to any 3rd-generation cephalosporin and susceptible to carbapenem



# Methods used by the AMASS application

## Data source:

For each run (double-click on AMASS.bat file), the AMASS application used the microbiology data file (microbiology\_data) and the hospital admission data file (hospital\_admission\_data) that were stored in the same folder as the application file. Hence, if the user would like to update, correct, revise or change the data, the data files in the folder should be updated before the AMASS.bat file is double-clicked again. A new report based on the updated data would then be generated.

## Requirements:

### – Computer with Microsoft Windows 7 or 10

AMASS may work in other versions of Microsoft Windows and other operating systems. However, thorough testing and adjustment have not been performed.

### – AMASS.zip package file

The AMASS application is to be downloaded from <http://www.amass.website>, and unzipped to generate an AMASS folder that could be stored under any folder in the computer. The AMASS folder contains 4 files (AMASS.bat, z\_Rcode.R, dictionary\_for\_microbiology\_data.xlsx, and dictionary\_for\_hospital\_admission\_data.xlsx), and 5 folders (Variables, Rprogram, Example\_Dataset\_1\_WHONET, Example\_Dataset\_2, and ResultData).

### – Microbiology data file (microbiology\_data in .csv or .xlsx file format)

The user needs to obtain microbiology data, and then copy & paste this data file into the same folder as the AMASS.bat file.

### – [Optional] Hospital admission data file (hospital\_admission\_data)

If available, the user could obtain hospital admission data, and then copy & paste this data file into the same folder as the AMASS.bat file.

## Not required:

### – Internet to run AMASS application

The AMASS application will run offline. No data are transferred while the application is running and reports are being generated; the reports are in PDF format (do not contain any patient identifier) and can be shared under the user's jurisdiction.

### – R

The download package (AMASS.zip) included R portable and R libraries that the AMASS application requires. The user does not need to install any programme before using the AMASS. The user also does not have to uninstall R programme if the computer already has the R programme installed. The user does not need to know how to use R programme.

**Note:**

[1] Please ensure that the file names of microbiology data file (microbiology\_data) and the hospital admission data file (hospital\_admission\_data) are identical to what is written here. Please make sure that all are lower-cases with an underscore '\_' at each space.

[2] Please ensure that both microbiology and hospital admission data files have no empty rows before the row of the variable names (i.e. the variable names are the first row in both files).

[3] For the first run, an user may need to fill the data dictionary files to make sure that the AMASS application understands your variable names and values.

AMASS uses a tier-based approach. In cases when only the microbiology data file with the results of culture positive samples is available, only section one and two would be generated for users. Section three would be generated only when data on admission date are available. This is because these data are required for the stratification by origin of infection. Section four would be generated only when data of specimens with culture negative (no microbial growth) are available in the microbiology data. This is because these are required for the sample-based approach. Section five would be generated only when both data of specimens with culture negative and admission date are available. Section six would be generated only when mortality data are available.

Mortality was calculated from the number of in-hospital deaths (numerator) over the total number of patients with blood culture positive for the organism (denominator). Please note that this is the all-cause mortality calculated using the outcome data in the data file, and may not necessarily represent the mortality directly due to the infections.

**How to use data dictionary files**

In cases when variable names in the microbiology and hospital admission data files were not the same as the one that AMASS used, the data dictionary files could be edited.

The raw microbiology and hospital admission data files were to be left unchanged.

The data dictionary files provided could be edited and re-used automatically when the microbiology and hospital admission data files were updated and the AMASS.bat were to be double-clicked again (i.e. the data dictionary files would allow the user to re-analyze data files without the need to adjust variable names and data value again every time).

For example:

If variable name for 'hospital number' is written as 'hn' in the raw data file, the user would need to add 'hn' in the cell next to 'hospital\_number'. If data value for blood specimens is defined by 'Blood–Hemoculture' in the raw data file, then the user would need to add 'Blood–Hemoculture' in the cell next to 'blood\_specimen'.

**Dictionary file (dictionary\_for\_microbiology\_data.xlsx) may show up as in the table below:**

Variable names used in AMASS	Variable names used in your microbiology data file	Requirements
Don't change values in this column, but you can add rows with similar values if you need	Change values in this column to represent how variable names are written in your raw microbiology data file	
hospital_number		Required
Values described in AMASS	Values used in your microbiology data file	Requirements
blood_specimen		Required

**Please fill in your variable names as follows:**

Variable names used in AMASS	Variable names used in your microbiology data file	Requirements
Don't change values in this column, but you can add rows with similar values if you need	Change values in this column to represent how variable names are written in your raw microbiology data file	
hospital_number	hn	Required
Values described in AMASS	Values used in your microbiology data file	Requirements
blood_specimen	Blood–Hemoculture	Required

Then, save the file. For every time the user double-clicked AMASS.bat, the application would know that the variable named 'hn' is similar to 'hospital\_number' and represents the patient identifier in the analysis.

**Organisms included in this report:**

- *Staphylococcus aureus*
- *Enterococcus* spp.
- *Streptococcus pneumoniae*
- *Salmonella* spp.
- *Escherichia coli*
- *Klebsiella pneumoniae*
- *Pseudomonas aeruginosa*
- *Acinetobacter* spp.

The eight organisms and antibiotics included in the report were selected based on the global priority list of antibiotic resistant bacteria and Global Antimicrobial Resistance Surveillance System (GLASS) of WHO [1,2].

**Definitions:**

The definitions of infection origin proposed by the WHO GLASS was used [1]. In brief, community–origin bloodstream infection (BSI) was defined for patients in the hospital within the first two calendar days of admission when the first blood culture positive specimens were taken. Hospital–origin BSI was defined for patients in the hospital longer than the first calendar days of admission when the first blood culture positive specimens were taken. In cases when the user had additional data on infection origin defined by infection control team or based on referral data, the user could edit the data dictionary file (variable name 'infection\_origin') and the AMASS application would use the data of that variable to stratify the data by origin of infection instead of the above definition. However, in cases when data on infection origin were not available (as in many hospitals in LMICs), the above definition would be calculated based on admission date and specimen collection date (with cutoff of 2 calendar days) and used to classify infections as community–origin or hospital–origin.

**De–duplication:**

When more than one blood culture was collected during patient management, duplicated findings of the same patient were excluded (de–duplicated). Only one result was reported for each patient per sample type (blood) and surveyed organisms (listed above). For example, if two blood cultures from the same patient had *E. coli*, only the first would be included in the report. If there was growth of *E. coli* in one blood culture and of *K. pneumoniae* in the other blood culture, then both results would be reported. One would be for the report on *E. coli* and the other one would be for the report on *K. pneumoniae*.

---

**References:**

[1] World Health Organization (2018) Global Antimicrobial Resistance Surveillance System (GLASS) Report. Early implantation 2016–2017. <http://apps.who.int/iris/bitstream/handle/10665/259744/9789241513449-eng.pdf>. (accessed on 3 Dec 2018)

[2] World Health Organization (2017) Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. [https://www.who.int/medicines/publications/WHO-PPL-Short\\_Summary\\_25Feb-ET\\_NM\\_WHO.pdf](https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf). (accessed on 3 Dec 2018)

## Investigator team

The AMASS application is being developed by Cherry Lim, Clare Ling, Elizabeth Ashley, Paul Turner, Rahul Batra, Rogier van Doorn, Soawapak Hinjoy, Sapon Iamsirithaworn, Susanna Dunachie, Tri Wangrangsimaikul, Viriya Hantrakun, William Schilling, John Stelling, Jonathan Edgeworth, Guy Thwaites, Nicholas PJ Day, Ben Cooper and Direk Limmathurotskul.

The AMASS application was funded by the Wellcome Trust (grant no. 206736 and 101103). C.L. is funded by a Training Research Fellowship (grant no. 206736) and D.L. is funded by an Intermediate Training Fellowship (grant no. 101103) from the Wellcome Trust.

